Today: 29 June 2026
Browse Category

NASDAQ:TOVX 16 October 2025 - 11 June 2026

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
11 June 2026
··
Theriva Biologics (TOVX) Stock Soars 92% on Oncolytic Virus Trial News – Can the Rally Last?

Theriva Biologics (TOVX) Stock Surges on Cancer Trial Breakthrough – What’s Next?

Theriva shares surged 92% intraday Oct. 15 after its VCN-01 therapy met primary endpoints in a Phase 2b pancreatic cancer trial, then fell back following a $4 million equity raise. Median survival in a two-dose subgroup reached 14.8 months versus 11.6 for chemo alone. The company held $12.1 million cash as of June 30, 2025, funding operations into early 2026. Expanded trial results will be presented at ESMO Oct. 20.
24 October 2025
·

Stock Market Today

  • Ryanair Faces Earnings Downgrades Amid Weak Summer Pricing and Rising Costs
    June 29, 2026, 5:48 AM EDT. Ryanair Holdings (RYAAY), Europe's largest low-cost airline, is under pressure as analysts cut earnings forecasts following a cautious outlook for the summer travel season. The company reported weaker-than-expected ticket pricing trends, with fares for the June quarter expected to decline mid-single digits year over year. Although passenger demand remains strong, lower average fares and delayed bookings amid economic uncertainty threaten profitability. Rising costs from fuel price volatility, airport charges, labor, and environmental taxes further strain margins. Ryanair's refusal to provide FY27 earnings guidance has compounded investor caution. Earnings per share estimates for FY27 have dropped 24% over the past 90 days, signaling increased near-term risk despite long-term strengths. The stock holds a Zacks Rank #5 (Strong Sell) and is named Bear of the Day.

Latest articles

ServiceNow (NYSE:NOW) stock: $9 billion Friday jump puts contract base back in focus

ServiceNow (NYSE:NOW) stock: $9 billion Friday jump puts contract base back in focus

29 June 2026
ServiceNow (NYSE:NOW) surged 9.85% to $98.34 Friday, adding $9.1 billion in equity value—about 72% of its $12.64 billion Q1 current remaining performance obligations—as software stocks outperformed amid rotation out of AI names; the move comes ahead of a potential near-term bookings catalyst tied to price increases and legacy tier retirements, with short interest at 5.82% of float.
Nvidia holds $47 billion-per-point sway as Nasdaq tries for bounce

Nvidia holds $47 billion-per-point sway as Nasdaq tries for bounce

29 June 2026
Nvidia’s $4.7 trillion market value means every 1% stock move shifts $47 billion, putting massive index risk in focus as AI capex spending faces fresh scrutiny from new BIS data and rising China chip competition, with premarket gains tested by funding and substitution risks.
Microsoft rebound ahead of Nasdaq open puts AI spending in spotlight

Microsoft rebound ahead of Nasdaq open puts AI spending in spotlight

29 June 2026
Microsoft surged 5.7% to $372.97 in premarket trading, adding $149 billion in market value, as investors weigh soaring AI-driven capex—Q3 spending was about twice free cash flow—against strong cloud growth and a $37 billion AI revenue run rate, while analysts warn higher costs could pressure margins.
Go toTop